7.95
-0.07 (-0.87%)
| Previous Close | 8.02 |
| Volume | 12,312 |
| Price / Sales | 0.410 |
| Price / Book | 4.95 |
| 52 Weeks Range |
| Profit Margin | -63.52% |
| Operating Margin (TTM) | -7.46% |
| Diluted EPS (TTM) | -1.31 |
| Quarterly Revenue Growth (YOY) | -11.20% |
| Total Debt/Equity (MRQ) | 300.69% |
| Current Ratio (MRQ) | 0.810 |
| Operating Cash Flow (TTM) | 3.02 M |
| Levered Free Cash Flow (TTM) | 5.51 M |
| Return on Assets (TTM) | -2.38% |
| Return on Equity (TTM) | -138.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | Harvard Bioscience, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | -0.57 |
|
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 8.27% |
| % Held by Institutions | 69.66% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |